Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Other/Immunotherapy

Immunotherapy

85

Pipeline Programs↗

101

Active Trials↗

45

Companies Involved↗

Immunotherapy is a moderately active landscape with 85 programs across 45 companies. The most active players are Medicenna Therapeutics, Inc., Abalos Therapeutics GmbH, Cytosite Biopharma Inc.. 12 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

74/100

Pipeline Velocity

47/100

Mech. Concentration

11/100

Completion Rate

83/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Medicenna Therapeutics, Inc.

1 program

Abalos Therapeutics GmbH

1 program

Cytosite Biopharma Inc.

1 program

Pipeline

Programs by Phase

Preclinical6

Peanut Flour OIT

Massachusetts General Hospital

PEG-Interferon Alfa-2b

Merck & Co.

Breastmilk

Al Adan Hospital Kuwait

Intra-Lesional MMR Immunotherapy

Abeer Mohamed Abdelaziz Elkholy

Immunotherapeutic Agent

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Phase 115

Peptide Pulsed Dendritic Cell

Universidad Nacional de Colombia

Cctl Treatment

Obstetrics & Gynecology Hospital of Fudan University

Zr-DFO-Emapalumab

Nerissa T. Viola

Intradermal Cat Allergen Challenge

National Institute of Allergy and Infectious Diseases (NIAID)

YE-NEO-001

NantBioScience, Inc.

Phase 252

Trastuzumab

Organon and Co

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Durvalumab

AstraZeneca

Ipilimumab

Bristol-Myers Squibb

Toripalimab

Coherus Oncology, Inc.

Phase 312

Megestrol Acetate and Olanzapine

Qingdao Central Hospital

Concurrent Lenvatinib

Trans Tasman Radiation Oncology Group

MET-4

University Health Network, Toronto

Pembrolizumab

Merck & Co.

Nivolumab

Bristol-Myers Squibb

Approved

No programs

Analysis

Modality Breakdown

69%

Small molecule

52 of 75 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 75 classified programs, each share of the total. Modality classified for 100% of 85 pipeline programs.

Analysis

Trial Status

304

clinical trials

Completed141 · 46%

Recruiting55 · 18%

Unknown status33 · 11%

Not yet recruiting24 · 8%

Active, not recruiting19 · 6%

Terminated18 · 6%

Other14 · 5%

Clinical Trials

Trial Activity

304 trials

The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer

Recruiting·FFudan University·Phase 2·NCT05555888·34 enrolled

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

Recruiting·GGuangdong Provincial People's Hospital·Phase 2·NCT06300424·32 enrolled

SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure

Recruiting·—·Phase 2·NCT07311408·40 enrolled

Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC

Recruiting·—·Phase 2·NCT06725498·50 enrolled

Nasal Mucus Proteome and Immunotherapy

Recruiting·MMedical University of Graz·N/A·NCT02159404·88 enrolled

Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab

Recruiting·RRegina Elena Cancer Institute·Phase 2·NCT06771518·37 enrolled

Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)

Recruiting·OOncology Center of Biochemical Education And Research·N/A·NCT06717243·111 enrolled

Immunotherapy in Patients With Early dMMR Rectal Cancer

Recruiting·OOdense University Hospital·Phase 2·NCT05732389·39 enrolled

A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC

Recruiting·GGrandPharma (China) Co., Ltd.·Phase 2·NCT07334483·120 enrolled

Nutrition Impact on Immunotherapy of Cancer

Recruiting·QQingdao Central Hospital·Phase 3·NCT06500234·300 enrolled

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

Recruiting·EEmory University·Phase 2·NCT07140679·40 enrolled

DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors

Recruiting·FFundación GECP·Phase 2·NCT05684276·22 enrolled

A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB

Recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 4·NCT05493267·30 enrolled

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

Recruiting·—·N/A·NCT06599619·30 enrolled

Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC

Recruiting·JJun Zhang, MD, PhD·N/A·NCT05332925·25 enrolled

Page 1 of 21

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)